• Product nameAnti-MCP1 antibody [24822.11]
    See all MCP1 primary antibodies
  • Description
    Mouse monoclonal [24822.11] to MCP1
  • Tested applicationsSuitable for: Neutralisingmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant human MCP-1 (rhMCP-1), expressed in E. coli.



Our Abpromise guarantee covers the use of ab10390 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesNeut: Use at a concentration of 0.1 µg/ml.

    Human MCP1 is tested for its ability to neutralize the chemoattractant activity of rhMCP1 for human monocytes. The ND50 of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of rhMCP1 that was present at a concentration just high enough to elicit a maximum response.

    In this bioassay, rhMCP1 was preincubated with various dilutions of the antibody for 1 hour at 37 °C in a 96-well microtiter plate. Then, the MCP1 antibody solution containing rhMCP1 at a final concentration of 0.1 µg/ml was transferred to the lower compartment of a 96-well chemotaxis chamber. The chemotaxis chamber was assembled using a PVP-free polycarbonate filter and the monocytes were added to the top chamber. The chamber was incubated for 90 minutes at 37 °C in a 5% CO2 humidified incubator. The chamber was disassembled and the filter fixed and stained. The optical density of the filter, which is proportional to the number of cells that migrated across the filter, was read with a microtiter plate reader set at 540 nm.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionChemotactic factor that attracts monocytes and basophils but not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis.
    • Sequence similaritiesBelongs to the intercrine beta (chemokine CC) family.
    • Post-translational
      Processing at the N-terminus can regulate receptor and target cell selectivity. Deletion of the N-terminal residue converts it from an activator of basophil to an eosinophil chemoattractant.
    • Cellular localizationSecreted.
    • Information by UniProt
    • Database links
    • Alternative names
      • C-C motif chemokine 2 antibody
      • CCL2 antibody
      • CCL2_HUMAN antibody
      • Chemokine (C C motif) ligand 2 antibody
      • GDCF 2 antibody
      • GDCF-2 antibody
      • GDCF2 antibody
      • HC11 antibody
      • HSMCR30 antibody
      • JE antibody
      • MCAF antibody
      • MCP 1 antibody
      • MCP-1 antibody
      • MCP1 antibody
      • MGC9434 antibody
      • Monocyte chemoattractant protein 1 antibody
      • Monocyte chemotactic and activating factor antibody
      • Monocyte chemotactic protein 1 antibody
      • Monocyte secretory protein JE antibody
      • SCYA2 antibody
      • Small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig je) antibody
      • Small inducible cytokine A2 antibody
      • Small inducible cytokine subfamily A (Cys Cys), member 2 antibody
      • Small-inducible cytokine A2 antibody
      • SMC CF antibody
      • SMC-CF antibody
      • SMCCF antibody
      see all

    References for Anti-MCP1 antibody [24822.11] (ab10390)

    ab10390 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab10390.
    Please use the links above to contact us or submit feedback about this product.